Emyria Limited (ASX: EMD) - Share Price
Current share price for EMD : $0.042 0.001 (2.44%)+
Emyria Limited (EMD), an ASX-listed company, is engaged in delivering and developing new treatments for mental health and selected neurological conditions. The Group's activities are informed by Real-World Data collected with patients across its wholly owned clinical service subsidiaries.
EMD General Information +
| ASX Code | EMD |
| Website | http://www.emyria.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 33 |
| EMD Share Price | $0.042 |
| Day High | $0.042 |
| Day Low | $0.041 |
| Last Close | $0.041 |
| EMD Share Price Movement | $0.00 ( 2.44% ) |
Prices as at 16:40, 12 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Emyria Limited (EMD) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Emyria Limited (EMD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Emyria Limited (EMD) price-sensitive announcements
EMD - Emyria Company Update Presentation
The presentation provides an update on Emyria Limited, highlighting its strategic focus on
Emyria Limited (EMD)
11 Jun 2026 | 9:10 AM
11 Jun 2026 | 9:10 AM
EMD - TGA Update to Accelerate Empax Therapist Recruitment
Emyria Limited announced updates from the Therapeutic Goods Administration (TGA) that sign
Emyria Limited (EMD)
28 May 2026 | 9:46 AM
28 May 2026 | 9:46 AM
EMD - Emyria Activates First Victorian Empax Clinic
Emyria Limited, a leader in innovative mental health treatments, has announced the activat
Emyria Limited (EMD)
18 May 2026 | 9:10 AM
18 May 2026 | 9:10 AM
EMD - March Quarter Investor Video Presentation
Emyria Limited's March Quarter Investor Video Presentation, held in May 2026, highlighted
Emyria Limited (EMD)
5 May 2026 | 8:34 AM
5 May 2026 | 8:34 AM
Emyria Limited (EMD) Recent ASX Announcements
EMD Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$3.15 | -$0.70 | -44.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$4.56 | -$1.30 | -28.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$5.13 | -$1.80 | -36.10% | 0.00 | 0.00 | 0.00% | 0.0% |
EMD Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $768M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Emyria Limited (EMD) | $33M | -0.4488 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $1,681M | -0.7857 | 0.0743 | 1.2000 | 57.1981 | 53.2400 | 24.2000 | 0.00% | 0.00% | 0.00% |
EMD Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 4.83 | 0.00 |
| Market | 0.32 | 12.90 | 1.16 | 0.66 |
| Sector | 0.40 | 27.30 | 2.56 | 2.10 |
EMD Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Michael Winlo | Managing Director | 8 Nov 2019 |
| Mr Greg Hutchinson | Non-Executive Chairman, Non-Executive Director | 21 Nov 2023 |
| Sir John Tooke | Non-Executive Director | 10 Feb 2020 |
| Dr Karen Smith | Non-Executive Director | 29 Nov 2021 |
| Dr Mohit Kaushal | Non-Executive Director | 21 Aug 2023 |
Emyria Limited (EMD) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 29 Aug 2025 | HUTCHINSON, Greg | Issued | Indirect Shares | 7,583,333 | $0.024 | $181,999.992 |
| 29 Aug 2025 | WINLO, Michael | Issued | Direct Shares | 208,333 | $0.024 | $4,999.992 |
| 4 Apr 2025 | WINLO, Michael | Buy | Direct Shares | 69,378 | $0.027 | $1,873.206 |
See all changes in directors' interest & trades for Emyria Limited (EMD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
EMD Management
| Name | Position |
|---|---|
| Sir John Tooke | Chair of Clinical Advisory |
| Mary Ann Rennie | Chief Operating Officer |
| Susan Patricia Park | Company Secretary |
| Claudia Sullivan | Head of Clinical Governance |
| Tatjana Heinrich | Head of Preclinical Drug Development |
| Claire Kullack | Lead Therapist |
| Clare Kullack | Lead Therapist |
| Matt Piggot | Leads Emyria's Medicinal Chemistry Program |
| Jon Laugharne | Medical Director/Lead Psychiatrist |
| Adrienne Smith | Project Manager |
EMD Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Emyria Limited (EMD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 54,788,694 (8.25%) | Mal Washer Nominees Pty Ltd |
| 35,071,429 (7.14%) | Gregory Hutchinson |
| 19,655,556 (5.47%) | Mercator Shipwrights Pty Ltd |
EMD Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 09 October 2026 | Report (Annual) |
| 27 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
